You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Dermatology

UCARE 2023: Role of Type 2 Inflammation in CSU Pathogenesis 

Dr. Saini provides a deep dive into the pathophysiology of type 2 inflammation in CSU.
Sarbjit Saini
MD
Sarbjit Saini

Learning objectives

  • Learn about the role of type 2 inflammation in the pathogenesis of CSU

Description

Dr. Saini provides a concise overview of CSU pathophysiology, including underlying mechanisms and the role of mast cells, other immune cells, and type 2 inflammatory cytokines. This video was recorded at the UCARE 2023 conference during the ADVENT symposium ‘Targeting Type 2 Inflammation in CSU – Clinical and Mechanistic Implications’.

Tags
expert insightsmechanism of diseasesymposiumtype 2 inflammation
MAT-GLB-2306108 V2.0 02/2024

About this expert

Allergy/Immunology

Sarbjit Saini

MD

Professor of Medicine, Johns Hopkins University School of Medicine in Baltimore, Maryland, United States

See author’s profile
Sarbjit Saini

Related resources

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management
Dermatology
Infographic

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

Expert Case Series: What is the Role of Type 2 Inflammation in Skin Barrier Dysfunction Commonly Observed in Atopic Dermatitis?
Dermatology
interactivity

Expert Case Series: What is the Role of Type 2 Inflammation in Skin Barrier Dysfunction Commonly Observed in Atopic Dermatitis?

Tools for Clinical Assessment of Prurigo Nodularis
Dermatology
Infographic

Tools for Clinical Assessment of Prurigo Nodularis

Can Emerging Treatments Help Address Individual PN Patient Burden?
Dermatology
expert video

Can Emerging Treatments Help Address Individual PN Patient Burden?

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children
Dermatology
expert video

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children - Expert Interview
Dermatology
expert video

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children - Expert Interview

Differences in Manifestations of Type 2 Inflammatory Diseases
Dermatology
expert video

Differences in Manifestations of Type 2 Inflammatory Diseases

Exploring Prurigo Nodularis: From Definition to Pathology and Patient Management
Dermatology
expert video

Exploring Prurigo Nodularis: From Definition to Pathology and Patient Management

EAACI 2023 | What is New in the Treatment of Children
Dermatology
expert video

EAACI 2023 | What is New in the Treatment of Children

Early Intervention in AD: Latest Clinical and Real-world Data
Dermatology
expert video

Early Intervention in AD: Latest Clinical and Real-world Data

Early Intervention in Children with Atopic Dermatitis: A Window of Opportunity?
Dermatology
expert video

Early Intervention in Children with Atopic Dermatitis: A Window of Opportunity?

Mast Cells and the Neuroimmune Axis in CSU
Dermatology
expert video

Mast Cells and the Neuroimmune Axis in CSU

New Perspectives in Understanding the Pathophysiology of Atopic Dermatitis in Children
Dermatology
expert video

New Perspectives in Understanding the Pathophysiology of Atopic Dermatitis in Children

PN is Considered a Unique Clinical Entity Distinct from Other Pruritic Diseases and Psychiatric Conditions
Dermatology
expert video

PN is Considered a Unique Clinical Entity Distinct from Other Pruritic Diseases and Psychiatric Conditions

Targeting Type 2 Inflammation in Children with AD​
Dermatology
expert video

Targeting Type 2 Inflammation in Children with AD​

IL-4 and IL-13: Shared and Unique Roles in Atopic Dermatitis (AD) and Prurigo Nodularis (PN)
Dermatology
expert video

IL-4 and IL-13: Shared and Unique Roles in Atopic Dermatitis (AD) and Prurigo Nodularis (PN)

Immune System, Microbiome and Neuroimmune Crosstalk in the Skin: Implications for AD
Dermatology
expert video

Immune System, Microbiome and Neuroimmune Crosstalk in the Skin: Implications for AD

Importance of Barrier Dysfunction in Driving AD Pathophysiology
Dermatology
expert video

Importance of Barrier Dysfunction in Driving AD Pathophysiology

How Should We Define and Classify Prurigo Nodularis?
Dermatology
expert video

How Should We Define and Classify Prurigo Nodularis?

Practical Considerations for the Management of Children With Moderate-to-severe Atopic Dermatitis
Dermatology
expert video

Practical Considerations for the Management of Children With Moderate-to-severe Atopic Dermatitis

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis
Dermatology
expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis

Targeting Type 2 Inflammation: ​Skin Barrier Normalization​
Dermatology
expert video

Targeting Type 2 Inflammation: ​Skin Barrier Normalization​

Type 2 Inflammation Modulates the Neuroimmune Axis in PN
Dermatology
expert video

Type 2 Inflammation Modulates the Neuroimmune Axis in PN

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis
Dermatology
expert video

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

What Drives PN Disease? Exploring the Complexity of PN Pathophysiology
Dermatology
expert video

What Drives PN Disease? Exploring the Complexity of PN Pathophysiology

Type 2 Inflammation Alters the Structure and Function of the Skin in AD
Dermatology
expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in AD

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis
Dermatology
videoanimation

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

Exploring Neurosensitization and Pain in Prurigo Nodularis
Dermatology
expert video

Exploring Neurosensitization and Pain in Prurigo Nodularis

The Impact of Skin Fibrosis in Patients with Prurigo Nodularis
Dermatology
videoanimation

The Impact of Skin Fibrosis in Patients with Prurigo Nodularis

Describing Disease Control in PN
Dermatology
expert video

Describing Disease Control in PN

What is Early Intervention in AD?
Dermatology
expert video

What is Early Intervention in AD?

Disease Modification in AD
Dermatology
expert video

Disease Modification in AD

Systemic Inflammation in AD – Beyond the Skin
Dermatology
expert video

Systemic Inflammation in AD – Beyond the Skin

Dysbiosis, Skin Infections, and Itch
Dermatology
expert video

Dysbiosis, Skin Infections, and Itch

Skin Barrier Dysfunction in AD
Dermatology
expert video

Skin Barrier Dysfunction in AD

Early Intervention and the Potential for Disease Modification in Children With AD
Dermatology
expert video

Early Intervention and the Potential for Disease Modification in Children With AD

Emerging Data on Advanced Systemic Treatments for Children With AD
Dermatology
expert video

Emerging Data on Advanced Systemic Treatments for Children With AD

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD
Dermatology
expert video

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis
Dermatology
expert video

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GreeceChange country/region